Edwards Lifesciences (EW) officer exercises options and sells 1,019 shares

Rhea-AI Filing Summary

Edwards Lifesciences reported an insider transaction by a company officer serving as CVP, JAPAC. On 12/12/2025, the officer exercised an employee stock option for 1,019 shares of common stock at an exercise price of $59.2567 per share, then sold the same 1,019 shares in the open market at a weighted average price of $84.0287, with individual sale prices ranging from $83.58 to $84.46.

After these transactions, the officer directly held 22,001.9103 shares of Edwards Lifesciences common stock and 5,095 employee stock options. The filing states that the trades were carried out under a Rule 10b5‑1 trading plan adopted on July 30, 2025, which is a pre-arranged plan intended to allow insiders to sell shares over time according to preset instructions.

Insider Trade Summary

Net Seller: 1,019 shares ($85,625)

Net Sell 3 txns

Insider Lippis Daniel J.

Role CVP, JAPAC

Sold 1,019 shs ($86K)

Type	Security	Shares	Price	Value
Exercise	Employee Stock Option (Right to Acquire)	1,019	$0.00	--
Exercise	Common Stock	1,019	$59.2567	$60K
Sale	Common Stock	1,019	$84.0287	$86K

Holdings After Transaction: Employee Stock Option (Right to Acquire) — 5,095 shares (Direct); Common Stock — 23,020.91 shares (Direct)

Footnotes (1)

1. The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 30, 2025. This transaction was executed in multiple trades at prices ranging from $83.58 to $84.46. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, uponrequest by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Lippis Daniel J.

(Last) (First) (Middle)

ONE EDWARDS WAY

(Street)

IRVINE CA 92614

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Edwards Lifesciences Corp [ EW ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CVP, JAPAC

3. Date of Earliest Transaction (Month/Day/Year)
12/12/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	12/12/2025		M(1)		1,019	A	$59.2567	23,020.9103	D
Common Stock	12/12/2025		S(1)		1,019	D	$84.0287(2)	22,001.9103	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (Right to Acquire)	$59.2567	12/12/2025		M			1,019	05/08/2020	05/07/2026	Common Stock	1,019	$0.0000	5,095	D

Explanation of Responses:

1. The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 30, 2025.

2. This transaction was executed in multiple trades at prices ranging from $83.58 to $84.46. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, uponrequest by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.

Remarks:

This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person.

	Linda J. Park, Attorney-in-Fact	12/12/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Edwards Lifesciences (EW) report in this Form 4?

An officer of Edwards Lifesciences reported exercising an employee stock option for 1,019 shares at $59.2567 per share and selling 1,019 shares of common stock at a weighted average price of $84.0287 on 12/12/2025.

How many Edwards Lifesciences (EW) shares does the reporting person own after the transaction?

Following the reported trades, the officer directly beneficially owned 22,001.9103 shares of Edwards Lifesciences common stock and held 5,095 employee stock options.

Was the Edwards Lifesciences (EW) insider trade under a Rule 10b5-1 plan?

Yes. The filing explains that the transactions were effected pursuant to a Rule 10b5‑1 trading plan adopted by the reporting person on July 30, 2025.

What price range were the Edwards Lifesciences (EW) shares sold for in this Form 4?

The 1,019 shares of Edwards Lifesciences common stock were sold in multiple trades at prices ranging from $83.58 to $84.46, with a weighted average sale price of $84.0287.

What is the reporting person’s role at Edwards Lifesciences (EW)?

The reporting person is identified as an officer of Edwards Lifesciences, holding the title CVP, JAPAC.

What were the key terms of the exercised Edwards Lifesciences (EW) stock option?

The derivative security was an employee stock option with an exercise price of $59.2567 per share, exercisable beginning 05/08/2020 and expiring on 05/07/2026, covering 1,019 shares of common stock.